

Peter C Taylor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1324866/peter-c-taylor-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

5,379
citations

37
h-index

71
g-index

156
ext. papers

6,957
ext. citations

6.3
avg, IF

6.26
L-index

#	Paper	IF	Citations
123	Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients satisfaction: a cross-sectional survey by patient organisations.. <i>BMJ Open</i> , 2022 , 12, e050949	3	0
122	Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression.. <i>Journal of Autoimmunity</i> , 2022 , 128, 102810	15.5	0
121	Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies.. <i>Journal of Dermatological Treatment</i> , 2022 , 1-28	2.8	
120	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1606-1616	4.7	12
119	Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	8
118	Expression of Endogenous Putative TSH Binding Protein in Orbit. <i>Current Issues in Molecular Biology</i> , 2021 , 43, 1794-1804	2.9	1
117	Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. <i>Lupus</i> , 2021 , 30, 2124-2134	2.6	0
116	A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 85	5.7	8
115	TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. <i>Journal of Autoimmunity</i> , 2021 , 118, 102597	15.5	9
114	Neutralizing monoclonal antibodies for treatment of COVID-19. <i>Nature Reviews Immunology</i> , 2021 , 21, 382-393	36.5	227
113	Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab026	1.1	
112	Relationship between thyroid hormones and metabolic syndrome in a normal thyroid function population in Western China: a cross-sectional study based on both epidemiological and genetic analysis.. <i>Chinese Medical Journal</i> , 2021 , 135, 350-352	2.9	1
111	Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. <i>Rheumatology</i> , 2021 , 60, 4972-4981	3.9	2
110	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. <i>RMD Open</i> , 2021 , 7,	5.9	2
109	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021 , 60, 2256-2266	3.9	5
108	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 305-317	40	42
107	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. <i>Patient Preference and Adherence</i> , 2021 , 15, 359-373	2.4	9

106	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 278-284	5.3	22
105	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
104	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2021 , 48, 1259-1267	4.1	3
103	Central sensitisation: causes, therapies, and terminology. <i>Lancet Rheumatology, The</i> , 2021 , 3, e546-e547	14.2	
102	Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. <i>BMJ Open</i> , 2021 , 11, e049850	3	
101	Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to target. <i>RMD Open</i> , 2021 , 7,	5.9	2
100	Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course. <i>Scientific Reports</i> , 2020 , 10, 8830	4.9	6
99	Adopting PROs in virtual and outpatient management of RA. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 477-478	8.1	11
98	Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making. <i>Patient Preference and Adherence</i> , 2020 , 14, 119-131	2.4	9
97	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , 2020 , 47, 658-667	4.1	3
96	Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 112-119	1.4	2
95	Update on the diagnosis and management of early rheumatoid arthritis. <i>Clinical Medicine</i> , 2020 , 20, 561-564	5.4	6
94	Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. <i>Rheumatology and Therapy</i> , 2020 , 7, 173-190	4.4	18
93	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020 , 72, 714-725	9.5	18
92	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 1056-1067	2.2	0
91	Treating to target or treating the patient in rheumatoid arthritis?. <i>Lancet Rheumatology, The</i> , 2019 , 1, e8-e10	14.2	3
90	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019 , 28, 2455-2470.e5	10.6	100
89	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17

88	Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. <i>BioDrugs</i> , 2019 , 33, 683-691	7.9	3
87	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1042-1055	9.5	82
86	MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 887-895	4.1	6
85	Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25
84	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1033-1040	2.4	21
83	Role of Hyaluronan in Human Adipogenesis: Evidence from in-Vitro and in-Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	3
82	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 890-898	2.4	13
81	How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	34
80	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.	5.7	34
79	Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1439-1441	2.4	
78	Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. <i>Trials</i> , 2019 , 20, 182	2.8	12
77	The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. <i>Viruses</i> , 2019 , 11,	6.2	12
76	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 761-772	2.4	96
75	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019 , 10, 279	5.6	57
74	Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. <i>Arthritis Research and Therapy</i> , 2019 , 21, 183	5.7	92
73	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019 , 20, 429	2.8	39
72	Role of biological agents in treatment of rheumatoid arthritis. <i>Pharmacological Research</i> , 2019 , 150, 104407	4.7	23
71	Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity. <i>BioDrugs</i> , 2019 , 33, 693-695	7.9	

70	SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 59-62	1.4	
69	Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, i17-i26	3.9	86
68	When the first visit to the rheumatologist is established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101479	5.3	3
67	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019 , 58, 1412-1418	2.4	43
66	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 958-966	5.3	2
65	The Odd Couple?-Hardly. <i>Rheumatology</i> , 2018 , 57, 1313-1315	3.9	1
64	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 988-995	2.4	31
63	Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 658-666	2.4	18
62	Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. <i>Rheumatology and Therapy</i> , 2018 , 5, 87-98	4.4	0
61	Sustained multimodal antimicrobial stewardship in an Australian tertiary intensive care unit from 2008-2015: an interrupted time-series analysis. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 620-628	14.3	8
60	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018 , 4, e000615	5.9	18
59	Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018 , 38, 935-947	3.6	65
58	The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies. <i>JMIR Research Protocols</i> , 2018 , 7, e165	2	12
57	Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 14-21	4.1	46
56	Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis: a Danish population-based regional cohort and qualitative implementation study. <i>BMJ Open</i> , 2018 , 8, e023915	3	6
55	The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. <i>Frontiers in Immunology</i> , 2018 , 9, 2226	8.4	36
54	Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018 , 12, 2007-2014	2.4	2
53	The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases. <i>Patient</i> , 2018 , 11, 515-526	3.7	3

52	Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation. <i>Journal of Rheumatology</i> , 2017 , 44, 748-756	4.1	12
51	Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 196-202	2.4	137
50	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 652-662	59.2	427
49	Advances in positron emission tomography for the imaging of rheumatoid arthritis. <i>Rheumatology</i> , 2017 , 56, 1837-1846	3.9	16
48	Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 2679-2690	7.3	110
47	Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. <i>Heart</i> , 2017 , 103, 766-773	5.1	29
46	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 943-952	9.5	31
45	Filgotinib for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1181-1187	5.9	30
44	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1853-1861	2.4	54
43	Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDDA) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. <i>Wellcome Open Research</i> , 2017 , 2, 37	4.8	10
42	The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory M1 macrophages. <i>PLoS ONE</i> , 2017 , 12, e0185767	3.7	41
41	Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. <i>Pathology</i> , 2016 , 48, 720-726	1.6	7
40	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. <i>Rheumatology International</i> , 2016 , 36, 685-95	3.6	154
39	Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression. <i>Rheumatology</i> , 2016 , 55, 89-93	3.9	17
38	Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. <i>PLoS ONE</i> , 2016 , 11, e0157961	3.7	14
37	Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 303	5.7	19
36	Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. <i>Lancet, The</i> , 2016 , 388, 239-47	4.0	76
35	Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 1072-1076	2.2	2

34	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2123-9	2.4	30
33	Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. <i>Expert Review of Clinical Immunology</i> , 2015 , 11 Suppl 1, S5-14	5.1	22
32	Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 2046-54	4.1	42
31	Anti-TNF therapy: past, present and future. <i>International Immunology</i> , 2015 , 27, 55-62	4.9	294
30	TNF α regulates cortisol metabolism in vivo in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 464-9	2.4	14
29	Early metacarpal bone mineral density loss using digital x-ray radiogrammetry and 3-tesla wrist MRI in established rheumatoid arthritis: a longitudinal one-year observational study. <i>Arthritis</i> , 2015 , 2015, 852989		6
28	Spondyloarthropathy: interleukin 23 and disease modification. <i>Lancet, The</i> , 2015 , 385, 2017-8	4.0	12
27	Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 333-40	2.4	188
26	Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. <i>PLoS ONE</i> , 2015 , 10, e0136982	3.7	7
25	A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study ¹ . <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A31.2-A31	2.4	7
24	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1475-80	2.4	91
23	Development of a multi-biomarker disease activity test for rheumatoid arthritis. <i>PLoS ONE</i> , 2013 , 8, e60635	3.5	117
22	Incomplete response of inflammatory arthritis to TNF α blockade is associated with the Th17 pathway. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1741-8	2.4	117
21	Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R198	5.7	17
20	Variation in the use of biologics in the management of rheumatoid arthritis across the UK. <i>Current Medical Research and Opinion</i> , 2012 , 28, 1733-41	2.5	8
19	Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, 254-61	2.2	23
18	Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2119-25	2.4	89
17	Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. <i>Journal of Rheumatology</i> , 2011 , 38, 2572-80	4.1	9

16	A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. <i>Autoimmune Diseases</i> , 2011 , 2011, 815038	2.9	74
15	Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids. <i>Journal of Rheumatology</i> , 2010 , 37, 2493-501	4.1	29
14	Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. <i>Current Opinion in Pharmacology</i> , 2010 , 10, 308-15	5.1	115
13	Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 917-28		96
12	The importance of the patients experience of RA compared with clinical measures of disease activity. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S28-31	2.2	41
11	How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 126-7	8.1	4
10	Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 578-82	8.1	275
9	MRI-detected bone marrow edema in early rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 516-7		
8	Anti- TNF Therapy of Rheumatoid Arthritis: What Can We Learn about Chronic Disease?. <i>Novartis Foundation Symposium</i> , 2008 , 53-73		30
7	Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. <i>Current Opinion in Biotechnology</i> , 2004 , 15, 557-63	11.4	51
6	Anti-TNF.ALPHA. Therapy for Rheumatoid Arthritis: An Update.. <i>Internal Medicine</i> , 2003 , 42, 15-20	1.1	75
5	Antibody therapy for rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2003 , 3, 323-8	5.1	65
4	The value of sensitive imaging modalities in rheumatoid arthritis. <i>Arthritis Research</i> , 2003 , 5, 210-3		38
3	Anti-TNFalpha therapy for rheumatoid arthritis: an update. <i>Internal Medicine</i> , 2003 , 42, 15-20	1.1	14
2	Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000 , 43, 38-47		337
1	Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1077-81		333